$3.16
0.07[2.27%]
At close: Apr 12
$3.16
0[0.00%]
PreMarket: 7:55PM EDT
Gain Therapeutics
(NASDAQ:GANX)Gain Therapeutics Stock (NASDAQ:GANX), Analyst Ratings, Price Targets, Predictions
Gain Therapeutics Inc has a consensus price target of $8.33, established from looking at the 21 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Chardan Capital, and HC Wainwright & Co. on April 1, 2024, March 27, 2024, and December 4, 2023. With an average price target of $8 between HC Wainwright & Co., Chardan Capital, and HC Wainwright & Co., there's an implied 153.16% upside for Gain Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Chardan Capital
Maxim Group
Oppenheimer
BTIG
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Gain Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/01/2024 | GANX | Buy Now | Gain Therapeutics | $3.16 | 184.81% | HC Wainwright & Co. | Raghuram Selvaraju | → $9 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | GANX | Buy Now | Gain Therapeutics | $3.16 | 89.87% | Chardan Capital | Keay Nakae | → $6 | Reiterates | Buy → Buy | Get Alert |
| 12/04/2023 | GANX | Buy Now | Gain Therapeutics | $3.16 | 184.81% | HC Wainwright & Co. | Raghuram Selvaraju | $10 → $9 | Maintains | Buy | Get Alert |
| 09/18/2023 | GANX | Buy Now | Gain Therapeutics | $3.16 | 216.46% | HC Wainwright & Co. | Raghuram Selvaraju | → $10 | Reiterates | Buy → Buy | Get Alert |
| 09/12/2023 | GANX | Buy Now | Gain Therapeutics | $3.16 | 216.46% | Maxim Group | Jason McCarthy | → $10 | Initiates | → Buy | Get Alert |
| 08/31/2023 | GANX | Buy Now | Gain Therapeutics | $3.16 | 216.46% | HC Wainwright & Co. | Raghuram Selvaraju | → $10 | Reiterates | Buy → Buy | Get Alert |
| 08/14/2023 | GANX | Buy Now | Gain Therapeutics | $3.16 | 89.87% | Chardan Capital | Keay Nakae | → $6 | Reiterates | Buy → Buy | Get Alert |
| 08/14/2023 | GANX | Buy Now | Gain Therapeutics | $3.16 | 216.46% | HC Wainwright & Co. | Raghuram Selvaraju | → $10 | Reiterates | Buy → Buy | Get Alert |
| 06/12/2023 | GANX | Buy Now | Gain Therapeutics | $3.16 | 216.46% | Oppenheimer | Hartaj Singh | → $10 | Reiterates | Outperform → Outperform | Get Alert |
| 05/15/2023 | GANX | Buy Now | Gain Therapeutics | $3.16 | 216.46% | HC Wainwright & Co. | Raghuram Selvaraju | → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | GANX | Buy Now | Gain Therapeutics | $3.16 | 89.87% | Chardan Capital | Keay Nakae | $5.75 → $6 | Maintains | Buy | Get Alert |
| 05/01/2023 | GANX | Buy Now | Gain Therapeutics | $3.16 | 216.46% | HC Wainwright & Co. | Raghuram Selvaraju | → $10 | Reiterates | → Buy | Get Alert |
| 03/27/2023 | GANX | Buy Now | Gain Therapeutics | $3.16 | 81.96% | Chardan Capital | Keay Nakae | $4 → $5.75 | Maintains | Buy | Get Alert |
| 12/09/2022 | GANX | Buy Now | Gain Therapeutics | $3.16 | 26.58% | Chardan Capital | Keay Nakae | → $4 | Initiates | → Buy | Get Alert |
| 11/25/2022 | GANX | Buy Now | Gain Therapeutics | $3.16 | 216.46% | Oppenheimer | Hartaj Singh | $30 → $10 | Maintains | Outperform | Get Alert |
| 11/14/2022 | GANX | Buy Now | Gain Therapeutics | $3.16 | 216.46% | HC Wainwright & Co. | Raghuram Selvaraju | $12 → $10 | Maintains | Buy | Get Alert |
| 11/14/2022 | GANX | Buy Now | Gain Therapeutics | $3.16 | 216.46% | BTIG | Thomas Shrader | $30 → $10 | Maintains | Buy | Get Alert |
| 08/19/2022 | GANX | Buy Now | Gain Therapeutics | $3.16 | 58.23% | B. Riley Securities | Mayank Mamtani | $11 → $5 | Downgrade | Buy → Neutral | Get Alert |
| 03/29/2022 | GANX | Buy Now | Gain Therapeutics | $3.16 | 406.33% | B. Riley Securities | Mayank Mamtani | $21 → $16 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Gain Therapeutics (GANX)?
The latest price target for Gain Therapeutics (NASDAQ: GANX) was reported by HC Wainwright & Co. on April 1, 2024. The analyst firm set a price target for $9.00 expecting GANX to rise to within 12 months (a possible 184.81% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Gain Therapeutics (GANX)?
The latest analyst rating for Gain Therapeutics (NASDAQ: GANX) was provided by HC Wainwright & Co., and Gain Therapeutics reiterated their buy rating.
When was the last upgrade for Gain Therapeutics (GANX)?
There is no last upgrade for Gain Therapeutics.
When was the last downgrade for Gain Therapeutics (GANX)?
The last downgrade for Gain Therapeutics Inc happened on August 19, 2022 when B. Riley Securities changed their price target from $11 to $5 for Gain Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Gain Therapeutics (GANX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gain Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gain Therapeutics was filed on April 1, 2024 so you should expect the next rating to be made available sometime around April 1, 2025.
Is the Analyst Rating Gain Therapeutics (GANX) correct?
While ratings are subjective and will change, the latest Gain Therapeutics (GANX) rating was a reiterated with a price target of $0.00 to $9.00. The current price Gain Therapeutics (GANX) is trading at is $3.16, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.